Perspective Therapeutics Presents Encouraging Incremental Data and Analyses from Phase 1/2a Trial of [212Pb]Bamzireotide Navoxetan (VMT-α-NET) in Advanced SSTR2 Expressing NETs

A retrospective subgroup analysis is informing a potential patient-selection strategy for a registration-enabling study.

Rhea-AI Summary

Perspective Therapeutics (CATX) reported additional Phase 1/2a data for bamzireotide navoxetan in patients with advanced neuroendocrine tumors expressing SSTR2 receptors. Among 57 patients with gastroenteropancreatic tumors whose target lesions all expressed SSTR2, the response rate was 39%, disease control was 95%, and survival without progression was 75% at 18 months. This subgroup analysis was retrospective, and response rates included responses awaiting confirmation.

Across 68 treated patients, no dose-limiting toxicities or treatment-related discontinuations were reported. Grade 3 treatment-emergent adverse events occurred in 29%; two patients experienced Grade 3 acute kidney injuries during follow-up. Perspective targets an end-of-Phase 2 meeting in the first quarter of 2027; Phase 3 initiation in 2027 depends on FDA feedback and completion of clinical, regulatory and operational activities.

13 points · 0 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 6 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Moderate pointResponse rates across treated patients were 37% overall, 33% in Cohort 2 and 50% in Cohort 3.
• Moderate pointDisease control across treated patients reached 91% overall, 89% in Cohort 2 and 95% in Cohort 3.
• Moderate pointSurvival without progression across treated patients was 85%, 74% and 72% at six, 12 and 18 months.
• Minor pointCohort 2 survival without progression was 83%, 71% and 69% at six, 12 and 18 months.
• Minor pointCohort 3 survival without progression was 90% at six months and 77% at 12 months.

8 minor points

• Minor pointSSTR2-positive GEP-NET subgroup response rates were 39% overall, 37% in Cohort 2 and 47% in Cohort 3.
• Minor pointSSTR2-positive GEP-NET subgroup disease control reached 95% overall, 92% in Cohort 2 and 100% in Cohort 3.
• Minor pointSubgroup survival without progression was 91%, 78% and 75% at six, 12 and 18 months.
• Minor pointSubgroup Cohort 2 survival without progression was 90%, 76% and 73% at six, 12 and 18 months.
• Minor pointSubgroup Cohort 3 survival without progression was 94% at six months and 78% at 12 months.
• Minor pointTreatment produced no dose-limiting toxicities, treatment-related discontinuations or drug-related serious adverse events during the treatment-emergent adverse-event window.
• Minor pointSafety monitoring reported no Grade 4 or 5 events and no myelodysplastic syndrome to date.
• Minor point. Forward-looking: it has not happened yet and may not happen.Perspective targets an end-of-Phase 2 meeting in the first quarter of 2027.

Negative

• Moderate pointGrade 3 treatment-emergent adverse events affected 20 of 68 patients (29%), including hematologic events in five (7.4%).
• Moderate point. Forward-looking: it has not happened yet and may not happen.Planned Phase 3 initiation in 2027 depends on FDA feedback and completion of clinical, regulatory and operational activities.
• Minor pointThe 57-patient subgroup analysis was retrospective; response rates include initial responses not yet confirmed.
• Minor pointSubgroup Cohort 3 responses included three awaiting confirmation; five of eight initial responses were confirmed.
• Minor pointGrade 3 acute kidney injuries affected two patients (3%); one possibly related event remains ongoing.
• Minor pointCreatinine rose above 2 mg/dL in one patient during subsequent therapy after discontinuation for disease progression.

News Explained

Perspective says it is bringing the all-target-lesions-SSTR2-positive GEP-NET findings into ongoing regulator discussions as a possible enrichment strategy for a registration-enabling study, so this release describes a design option under discussion, not a finalized study plan.

Key Figures

Subgroup size: 57 patients PFS: 75% at 18 months Disease control rate: 92% +5 more

Subgroup size

57 patients

GEP-NET patients with SSTR2 expression in all target lesions

PFS

75% at 18 months

GEP-NET subgroup across Cohorts 1–3

Disease control rate

92%

Cohort 2, GEP-NET subgroup

Disease control rate

100%

Cohort 3, GEP-NET subgroup

Response rate

37%

Cohort 2, GEP-NET subgroup

Response rate

47%

Cohort 3, GEP-NET subgroup

Grade 3 TEAEs

20 of 68 patients (29%)

All patients treated with bamzireotide

End-of-Phase 2 meeting target

1Q 2027

Company target

Previous Clinical trial Reports

1 past event · Latest: Oct 23

Same Type 1 event

1. Oct 23

   Phase 1/2a results

   24h Move

   -28.8%

   Earlier Phase 1/2a report supplied broader-cohort response and disease-control benchmarks for the same therapy.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

progression free survival, sstr2, objective response rate, disease control rate, +1 more

5 terms

progression free survival medical

"progression free survival (PFS) was 75% at 18 months"

Progression free survival is the length of time during and after a treatment when a disease, such as cancer, does not get worse or spread. It is an important measure because longer periods of stability can indicate that a treatment is effectively controlling the condition. For investors, it provides insight into the potential durability and success of a therapy or medication.

sstr2 medical

"somatostatin receptor type 2 (SSTR2) expressing neuroendocrine tumors"

sstr2 is a protein on the surface of some cells that acts like a lock for the hormone somatostatin and similar drugs; many neuroendocrine tumors have lots of these locks. For investors, sstr2 matters because tests and medicines that find or fit this lock — such as targeted imaging agents and therapies — can enable diagnosis, guide treatment decisions, and create commercial opportunities if they gain regulatory approval and clinical adoption.

objective response rate medical

"Objective response rate | 14 of 38 (37%)"

The objective response rate (ORR) is the percentage of patients in a clinical trial whose tumors measurably shrink or disappear according to preset rules. Investors use it as a quick, objective signal of a drug’s ability to produce a clear treatment effect—like counting how many plants visibly respond after applying a new fertilizer—and higher ORR can improve odds of regulatory approval, commercial success, and company valuation.

disease control rate medical

"Disease control rate includes complete response, partial response, and stable disease"

The disease control rate is the share of patients in a clinical trial whose cancer or condition either shrinks or stops getting worse for a specified period after treatment. Think of it like the percentage of people for whom a treatment hits pause or nudges back the problem rather than letting it progress; higher rates suggest the therapy can meaningfully limit disease, which matters to investors assessing a drug’s potential efficacy and commercial value.

dose-limiting toxicities medical

"There were no reports of dose-limiting toxicities"

Dose-limiting toxicities are the harmful side effects seen in early clinical trials that are severe enough to stop researchers from raising a drug’s dose. Like a car’s speed limiter marking the safe top speed, DLTs define the maximum tolerable dose, and they matter to investors because they determine whether a medicine can reach effective levels, influence development timelines, costs, and regulatory chances, and thus affect a drug’s commercial prospects.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• Additional analyses presented at NANETS 2026 Multidisciplinary NET Medical Symposium support prior findings of durable ongoing disease control and encouraging responses in all three cohorts across multiple patient populations
• Preliminary evidence of more robust anti-tumor activity and durable responses in GEP-NET patients whose target lesions all express SSTR2+ supports focusing on this population
• Bamzireotide continues to be well-tolerated
• Targeting End-of-Phase 2 meeting in 1Q 2027

SEATTLE, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced systemic treatments for cancers, today announced incremental data and analyses from its ongoing Phase 1/2a clinical trial of [²¹²Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing neuroendocrine tumors (NETs). These analyses were presented today in an oral presentation at the 2026 North American Neuroendocrine Tumors Society (NANETS) Multidisciplinary NET Medical Symposium taking place November 5-7, 2026 in Las Vegas, Nevada.

The NANETS presentation provided incremental data and analyses following the Company’s rapid oral presentation on October 23, 2026 at the European Society for Medical Oncology (ESMO) Congress 2026. Additional data were presented on 57 patients with gastroenteropancreatic (GEP) NETs whose target lesions all express SSTR2 who are enrolled in Cohorts 1-3 of the trial. Among these 57 patients: progression free survival (PFS) was 75% at 18 months; disease control was observed in 35 (92%) of 38 Cohort 2 patients and all 17 (100%) patients in Cohort 3; and responses were seen in 14 (37%) of 38 Cohort 2 patients and in 8 (47%) of 17 Cohort 3 patients.

“Deeper analyses of the substantial bamzireotide dataset are providing important insights into its clinical profile and its potential to benefit patients relative to an approved radiotherapy as shown in that therapy’s U.S. package insert of 13% ORR and ~65% PFS at 18 months,” said Markus Puhlmann, MD, Perspective’s Chief Medical Officer. “We are pleased to see a stronger signal in a subgroup of interest, specifically GEP-NETs patients whose target lesions all express SSTR2. Meanwhile, bamzireotide remains well-tolerated, with low incidence of high-grade adverse events. Long-term safety follow-up is ongoing, and these findings continue to be evaluated against natural history for organ function and pre-existing conditions of each patient.”

“These analyses support bringing bamzireotide expeditiously to patients, especially GEP-NETs patients whose target lesions all express SSTR2,” said Thijs Spoor, Perspective’s Chief Executive Officer. “We are incorporating these findings as a potential enrichment strategy into ongoing discussions with regulators on the design of a registration enabling study, and are targeting an end-of-Phase 2 meeting in the first quarter of 2027. FDA feedback and completion of the necessary clinical, regulatory, and operational activities are expected to enable initiation of the Phase 3 study in 2027.”

NANETS presentation highlights rationale for enrichment strategy
Across Cohorts 1-3 of the ongoing Phase 1/2 dose finding study, 68 patients received at least one treatment of bamzireotide. These patients received at least one treatment across three dose cohorts of up to 10 mCi, 20 mCi, and 24 mCi, respectively, split into four doses administered every eight weeks. Patients were followed for a median of 128 weeks in Cohort 1, 76 weeks in Cohort 2, and 34 weeks in Cohort 3, as of September 10, 2026.

Efficacy: Durable ongoing disease control and robust anti-tumor activities in all three cohorts across multiple patient populations

	GEP-NET SSTR2-positive in all target lesions*			All patients who received at least one treatment
	Cohort 2 (n=38)	Cohort 3 (n=17)	Cohorts 1- 3 (n=57)	Cohort 2 (n=46)	Cohort 3 (n=20)	Cohorts 1- 3 (n=68)
Objective response rate	14 of 38 (37%)	8 of 17 (47%)	22 of 57 (39%)	15 of 46 (33%)	10 of 20 (50%)	25 of 68 (37%)
Disease control rate	35 of 38 (92%)	17 of 17 (100%)	54 of 57 (95%)	41 of 46 (89%)	19 of 20 (95%)	62 of 68 (91%)
Landmark PFS at
6 months	90%	94%	91%	83%	90%	85%
12 months	76%	78%	78%	71%	77%	74%
18 months	73%	NE	75%	69%	NE	72%

*Retrospective subgroup analysis
Objective response rate includes confirmed and initial responses that have not yet been confirmed. All patients with unconfirmed initial responses remain in study and are expected to receive subsequent tumor assessment. Disease control rate includes complete response, partial response, and stable disease.

Findings from 57 GEP-NET patients in Cohorts 1-3 whose target lesions all express SSTR2

• Durable disease control: Disease control rate was 92% for Cohort 2 and 100% for Cohort 3. PFS rate was 91% at six months, 78% at 12 months, and 75% at 18 months across Cohorts 1, 2 and 3.
• Robust tumor responses: 14 out of 38 (37%) Cohort 2 patients experienced confirmed response as their best responses. A further 11 patients with stable disease in Cohort 2 remain in study as of September 10, 2026. In Cohort 3, 8 out of 17 patients experienced an initial response; five of those responses were confirmed. All three patients with responses pending confirmation remain in study and are expected to receive subsequent tumor assessments. A further 8 patients with stable disease in Cohort 3 remain in study as of September 10, 2026.

Safety: No dose-limiting toxicities and no discontinuations due to adverse events

Across all 68 patients who received at least one bamzireotide treatment:

• Bamzireotide continues to be well-tolerated. There were no reports of dose-limiting toxicities, no treatment-related discontinuations, and no serious adverse events related to study medication during the treatment emergent adverse event window.
  
  
• Low incidence of high-grade TEAEs were observed, all of which were Grade 3 (20 out of 68 patients, or 29%). No Grade 4 or 5 events were reported.
  
  
• Low incidence of high-grade hematologic TEAEs were observed, all of which were Grade 3 (five out of 68 patients, or 7.4%). No intervention required for lymphopenia. No myelodysplastic syndrome reported to date.
  
  
• Renal tolerability has remained acceptable, with ongoing follow-up. Grade 3 renal events were rare during ongoing study follow up, possibly not drug related. Two patients (3%) experienced Grade 3 renal events, both acute kidney injuries. One patient experienced the event approximately two years after their final treatment; the investigator assessed the event to be possibly related and the event is ongoing. For the second patient, the investigator assessed the event to be unlikely related to bamzireotide treatment, and the event has resolved.
  
  In addition, a creatinine level elevation to above 2 mg/dL was reported in one patient. This event occurred after the patient discontinued bamzireotide treatment without completing all four planned doses due to disease progression, and during a subsequent post-progression systemic therapy.

Upcoming conference presentation. The Company will exhibit a poster on bamzireotide at the EORTC-NCI-AACR (ENA) Symposium on November 20, 2026.

About [²¹²Pb]VMT-α-NET
Perspective designed [²¹²Pb]VMT-α-NET to target somatostatin receptor subtype 2 (SSTR2), and to deliver the alpha-emitting radioisotope lead-212, or ²¹²Pb, to tumor sites expressing SSTR2. The Company is conducting a multi-center, open-label, dose-escalation and dose-expansion study (clinicaltrials.gov identifier NCT05636618) of [²¹²Pb]VMT-α-NET in patients with unresectable or metastatic SSTR2-positive tumors who have not received prior radiopharmaceutical therapies (RPT).

About Neuroendocrine Tumors
Neuroendocrine tumors form in cells that interact with the nervous system or in glands that produce hormones. They can originate in various parts of the body, most often in the gut or the lungs, and can be benign or malignant. Neuroendocrine tumors are typically classified as pancreatic neuroendocrine tumors or non-pancreatic neuroendocrine tumors. According to cancer.net, it is estimated that more than 12,000 people in the United States are diagnosed with a NET each year. Importantly, neuroendocrine tumors are associated with a relatively long duration of survival compared to other tumors, and as a result, there are over 250,000 people living with this diagnosis.¹

About Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc. is a radiopharmaceutical development company pioneering advanced systemic treatments for cancers. The Company has proprietary technology that utilizes the alpha-generating isotope ²¹²Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging techniques that incorporate the same targeting moieties, creating an opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables visualization of the specific tumor and subsequent treatment, potentially improving efficacy and minimizing toxicity.

The Company is advancing a portfolio of clinical-stage programs in the U.S., including bamzireotide navoxetan (VMT-α-NET, neuroendocrine tumors), lapemelanotide zapixetar (VMT01, melanoma), and PSV359 (solid tumors).

The Company is expanding its regional finished drug product candidate supply network, enabled by its proprietary ²²⁴Ra/²¹²Pb generator platform used to manufacture clinical drug product candidates, to support the delivery of patient-ready drug product candidates for clinical trials and, if approved, commercial operations.

For more information, please visit the Company's website at www.perspectivetherapeutics.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Words such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "estimate," "believe," "predict," "potential," or "continue," or the negative of these terms or other similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements concerning, among other things, the Company’s proprietary technology, imaging techniques and product candidates, and related treatment opportunities; the Company’s understanding regarding the clinical profiles of its product candidates, including VMT-α-NET, PSV359, and VMT01; the Company’s preclinical and clinical development plans and the expected timing for the release of additional data from its clinical programs; the Company’s beliefs that its product candidates address certain unmet medical needs; the potential clinical benefits of the Company’s product candidates relative to existing therapies; the Company’s expectations regarding regulatory pathways for its product candidates; the Company’s expectations regarding its interactions with regulatory agencies, including the FDA, and the expected timing thereof; the Company’s expectations regarding an end-of-Phase 2 meeting with the FDA in the first quarter of 2027; the Company’s expectations that FDA feedback and completion of the necessary clinical, regulatory, and operational activities will enable initiation of the Phase 3 study in 2027; the Company’s regional distribution and manufacturing capabilities; the Company’s plan to exhibit a poster on VMT-α-NET at the EORTC-NCI-AACR Symposium; and other statements that are not historical fact.

The Company may not actually achieve the plans, intentions, or expectations disclosed in the forward-looking statements, and you should not place undue reliance on the forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements. Known risk factors include (without limitation) that the Company’s clinical trials may be more costly or take longer to complete than anticipated, or may never be completed, or may not generate results that warrant future development of the tested product candidate; regulatory authorities may not grant or may delay approval for our product candidates; the Company may elect to change its strategy regarding its product candidates and clinical development and manufacturing activities; our ability to successfully incorporate clinical data findings into ongoing discussions with regulators, including the FDA, on the designs of registration enabling studies; regulatory agencies may issue decisions that negatively impact the Company’s product candidates and clinical development plans; economic and market conditions may worsen; and risks related to the sufficiency of the Company’s cash resources for its future operating expenses and capital expenditures. A more complete discussion of the risks and uncertainties facing the Company appears under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”), in the Company’s other filings with the SEC, and in the Company’s future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Media and Investor Relations Contacts:

Perspective Therapeutics IR:
Annie J. Cheng, CFA
ir@perspectivetherapeutics.com

ENTENTE Network of Companies
Katie Morris, PhD
katiemorris@ententeinc.com

---

¹ Dasari A et al. JAMA Netw Open 2025;8:e2515798.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Perspective Therapeutics report for the bamzireotide GEP-NET subgroup?

Among 57 patients whose target lesions all expressed SSTR2, the objective response rate was 39%, disease control was 95%, and survival without progression was 75% at 18 months. The analysis was retrospective, and the response rate included initial responses awaiting confirmation.

When could Perspective Therapeutics start a Phase 3 bamzireotide study?

Perspective expects FDA feedback and completion of necessary clinical, regulatory and operational activities to enable Phase 3 initiation in 2027. The company targets an end-of-Phase 2 meeting in the first quarter of 2027 and is discussing a potential patient-selection strategy focused on GEP-NET patients whose target lesions all express SSTR2.

How was Perspective Therapeutics' Phase 1/2a bamzireotide trial designed?

The trial is a multicenter, open-label dose-escalation and dose-expansion study in patients with unresectable or metastatic SSTR2-positive tumors who had not received prior radiopharmaceutical therapies. The three cohorts received up to 10 mCi, 20 mCi and 24 mCi, respectively, split into four doses administered every eight weeks.

How long were patients followed in Perspective Therapeutics' bamzireotide trial?

As of September 10, 2026, median follow-up was 128 weeks in Cohort 1, 76 weeks in Cohort 2 and 34 weeks in Cohort 3. Across the three cohorts, 68 patients had received at least one treatment.